References

Alsaab, H. O., Altowairqi, E., Alzahrani, N., Alzahrani, R., Alshehri, F. S., Almalki, A. H., ... & Althobaiti, Y. S. (2020). Sex differences in pregabalin-seeking like behavior in a conditioned place preference paradigm. *Saudi Pharmaceutical Journal*, *28*(12), 1749-1755.

Althobaiti, Y. S. (2024). Oral self-administration of pregabalin in a mouse model and the resulting drug addiction features. *Saudi Pharmaceutical Journal*, *32*(2), 101935.

Althobaiti, Y. S., Alghorabi, A., Alshehri, F. S., Baothman, B., Almalki, A. H., Alsaab, H. O., Alsanie, W., Gaber, A., Almalki, H., Alghamdi, A. S., Basfer, A., Althobaiti, S., Hardy, A. M. G., & Shah, Z. A. (2020). Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system. *Scientific reports*, *10*(1), 10445. https://doi.org/10.1038/s41598-020-67318-6

Althobaiti, Y. S., Almalki, A., Alsaab, H., Alsanie, W., Gaber, A., Alhadidi, Q., Hardy, A. M. G., Nasr, A., Alzahrani, O., Stary, C. M., & Shah, Z. A. (2019). Pregabalin: Potential for Addiction and a Possible Glutamatergic Mechanism. *Scientific reports*, *9*(1), 15136. https://doi.org/10.1038/s41598-019-51556-4

Andrews, N., Loomis, S., Blake, R., Ferrigan, L., Singh, L., & McKnight, A. T. (2001). Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. *Psychopharmacology*, *157*(4), 381–387. https://doi.org/10.1007/s002130100839

Backonja, M., & Glanzman, R. L. (2003). Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clinical therapeutics, 25(1), 81–104. https://doi.org/10.1016/s0149-2918(03)90011-7

Bastiaens, L., Galus, J., & Mazur, C. (2016). Abuse of Gabapentin is Associated with Opioid Addiction. *The Psychiatric quarterly*, *87*(4), 763–767. https://doi.org/10.1007/s11126-016-9421-7

Besheer, J., Frisbee, S., Randall, P. A., Jaramillo, A. A., & Masciello, M. (2016). Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats. *Neuropharmacology*, *101*, 216–224. https://doi.org/10.1016/j.neuropharm.2015.09.027

Cheng, J. K., & Chiou, L. C. (2006). Mechanisms of the antinociceptive action of gabapentin. *Journal of pharmacological sciences*, *100*(5), 471–486. https://doi.org/10.1254/jphs.cr0050020

Domon, Y., Arakawa, N., Inoue, T., Matsuda, F., Takahashi, M., Yamamura, N., ... & Kitano, Y. (2018). Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels. *The Journal of pharmacology and experimental therapeutics*, *365*(3), 573-582.

Filip, M., Frankowska, M., Zaniewska, M., Gołda, A., Przegaliński, E., & Vetulani, J. (2007). Diverse effects of GABA-mimetic drugs on cocaine-evoked self-administration and discriminative stimulus effects in rats. *Psychopharmacology*, *192*(1), 17–26. https://doi.org/10.1007/s00213-006-0694-7

Garnier, C., Schein, M., Lacroix, C., Jouve, E., Soeiro, T., Gentile, G., ... & Micallef, J. (2024). Patterns of pregabalin users from substance abuse treatment facilities: results from the French OPPIDUM program from 2008 to 2022. *CNS drugs*, *38*(9), 743-751.

Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W. (2017). Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. *PLoS medicine*, *14*(10), e1002396. https://doi.org/10.1371/journal.pmed.1002396

Haney, M., Hart, C., Collins, E. D., & Foltin, R. W. (2005). Smoked cocaine discrimination in humans: effects of gabapentin. *Drug and alcohol dependence*, *80*(1), 53–61. https://doi.org/10.1016/j.drugalcdep.2005.03.006

Harding, E. K., Souza, I. A., Gandini, M. A., Gadotti, V. M., Ali, M. Y., Huang, S., Antunes, F. T. T., Trang, T., & Zamponi, G. W. (2023). Differential regulation of $Ca_v3.2$ and Ca_v 2.2 calcium channels by CB_1 receptors and cannabidiol. *British journal of pharmacology*, *180*(12), 1616–1633. https://doi.org/10.1111/bph.16035

Hart, C. L., Haney, M., Vosburg, S. K., Rubin, E., & Foltin, R. W. (2007). Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. *Behavioural pharmacology*, *18*(1), 71–75. https://doi.org/10.1097/FBP.0b013e328014139d

Hiranita, T., Flynn, S. M., Grisham, A. K., Mijares, A. E., Murphy, E. N., & France, C. P. (2024). Gabapentinoids Increase the Potency of Fentanyl and Heroin and Decrease the Potency of Naloxone to Antagonize Fentanyl and Heroin in Rats Discriminating Fentanyl. *The Journal of pharmacology and experimental therapeutics*, *391*(2), 317–334. https://doi.org/10.1124/jpet.124.002323

Ispir, G. Z., Danısman, M., & Katar, K. S. (2025). A Hidden Pandemic? Abuse of Gabapentinoids: A Brief Review of Recent Studies. *Current drug research reviews*, *17*(1), 5–9. https://doi.org/10.2174/0125899775268780231002064605

Johansen, M. E., & Maust, D. T. (2024). Update to Gabapentinoid Use in the United States, 2002-2021. *Annals of family medicine*, *22*(1), 45–49. https://doi.org/10.1370/afm.3052

Kranzler, H. R., Feinn, R., Morris, P., & Hartwell, E. E. (2019). A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. *Addiction (Abingdon, England)*, *114*(9), 1547–1555. https://doi.org/10.1111/add.14655

Kricek, F., Ruf, C., Meghani, P., Souza, I. A., Gandini, M. A., Zamponi, G. W., & Skouteris, G. (2024). A next generation peripherally restricted Cavα2δ-1 ligand with inhibitory action on Cav2.2 channels and utility in neuropathic pain. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, *174*, 116472. https://doi.org/10.1016/j.biopha.2024.116472

Levine, A. R., Carrasquillo, L., Mueller, J., Nounou, M. I., Naut, E. R., & Ibrahim, D. (2019). High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis. *Pharmacotherapy*, *39*(9), 881–888. https://doi.org/10.1002/phar.2309

Li, Z., Taylor, C. P., Weber, M., Piechan, J., Prior, F., Bian, F., ... & Donevan, S. (2011). Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2 calcium channel subunits. *European journal of pharmacology*, *667*(1-3), 80-90.

Lile, J. A., Wesley, M. J., Kelly, T. H., & Hays, L. R. (2016). Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol. *Behavioural pharmacology*, *27*(2-3 Spec Issue), 215–224. https://doi.org/10.1097/FBP.0000000000000187

Marais, E., Klugbauer, N., & Hofmann, F. (2001). Calcium channel alpha(2)delta subunits-structure and Gabapentin binding. *Molecular pharmacology*, *59*(5), 1243–1248. https://doi.org/10.1124/mol.59.5.1243

Mattson, C. L. (2022). Notes from the field: trends in gabapentin detection and involvement in drug overdose deaths—23 states and the District of Columbia, 2019–2020. *MMWR. Morbidity and mortality weekly report*, *71*.

Olopoenia, A., Camelo-Castillo, W., Qato, D. M., Adekoya, A., Palumbo, F., Sera, L., & Simoni-Wastila, L. (2022). Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: A nested case-control study. *Lancet regional health. Americas*, *13*, 100302. https://doi.org/10.1016/j.lana.2022.100302

Park, H. J., Sandor, K., McQueen, J., Woller, S. A., Svensson, C. I., Corr, M., & Yaksh, T. L. (2016). The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. *European journal of pain (London, England)*, *20*(6), 917–925. https://doi.org/10.1002/ejp.816

Peng, X. Q., Li, X., Li, J., Ramachandran, P. V., Gagare, P. D., Pratihar, D., Ashby, C. R., Jr, Gardner, E. L., & Xi, Z. X. (2008). Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats. *Drug and alcohol dependence*, *97*(3), 207–215. https://doi.org/10.1016/j.drugalcdep.2007.09.019

Pirec, V., Laurito, C. E., Lu, Y., & Yeomans, D. C. (2001). The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. *Anesthesia and analgesia*, *92*(1), 239–243. https://doi.org/10.1097/00000539-200101000-00046

Pollack, M. H., Matthews, J., & Scott, E. L. (1998). Gabapentin as a potential treatment for anxiety disorders. The American journal of psychiatry, 155(7), 992–993. https://doi.org/10.1176/ajp.155.7.992

Prus, A. J., Van Fossen, M. T., Iannucci, A. N., Dalton, A. G., & Prete, J. N. (2024). Discriminative stimulus properties of two training doses of gabapentin in rats: Substitution by pregabalin, diazepam, and pentobarbital. *Experimental and clinical psychopharmacology*, *32*(4), 485–495. https://doi.org/10.1037/pha0000704

Roberto, M., Gilpin, N. W., O'Dell, L. E., Cruz, M. T., Morse, A. C., Siggins, G. R., & Koob, G. F. (2008). Cellular and behavioral interactions of gabapentin with alcohol dependence. Journal of Neuroscience, 28(22), 5762-5771.

Souza, I. A., Gandini, M. A., Ali, M. Y., Kricek, F., Skouteris, G., & Zamponi, G. W. (2024). Determinants of interactions of a novel next-generation gabapentinoid NVA1309 and mirogabalin with the Cavα2δ-1 subunit. *Molecular Brain*, *17*(1), 54.